Preliminary Prospectus Supplement

• Anteris Technologies files Preliminary Prospectus Supplement with U.S. SEC
• Concurrent private placement with Medtronic subsidiary for up to $90M
• Offering and private placement to support Anteris' growth and development

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), a global structural heart company, has filed the attached Preliminary Prospectus Supplement with the U.S. Securities and Exchange Commission (SEC) on 20 January 2026 US Eastern time (21 January 2026 AEST). The company is offering $200 million of shares of its common stock pursuant to the prospectus supplement and the accompanying prospectus. Concurrently with this offering, Anteris has agreed to sell up to $90 million of shares of common stock to Covidien Group S.à r.l., a wholly-owned subsidiary of Medtronic plc, through a private placement. The private placement is subject to a minimum purchase of 16% and a maximum purchase of 19.99% of the number of shares of common stock outstanding after the offering and the private placement. The completion of the private placement is contingent on the completion of the public offering. The net proceeds from the offering and the private placement are expected to be used to support Anteris' growth and development, including the continued clinical evaluation of its lead product, the DurAVR® Transcatheter Heart Valve (THV) System, in the PARADIGM Trial.